Home About Us Pipeline Partnerships Investors News & Events Careers Contact Us
S*BIO Vision | Background | S*BIO Management | Board of Directors | Scientific Advisory Board | Corporate Values
Clinical Trials | Technologies & Capabilities
News & Press Releases | Participation in Events | Publications
Join Our Team | Career Opportunities

The best scientist is open to experience and begins with romance - the idea that anything is possible.
Ray Bradbury


News & Press Releases


13 June 2010 - S*BIO Presents Positive Safety and Tolerability Results for its Novel Oral JAK2 Inhibitor SB1518 from a Phase 1/2 Study for the Treatment of Myelofibrosis (MF)
9 June 2010 - S*BIO Completes Enrollment of Patients in Phase 2 Clinical Trials for its JAK2 Inhibitor SB1518
4 May 2010 - S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors
2 December 2009 - S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and other Hematological Disorders
18 March 2009 - S*BIO Receives BioSingapore’s 2009 Award for the Most Successful Bio-Partnership in Asia

6 March 2009 - S*BIO Receives BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award

21 January 2009 - S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317

6 January 2009 - S*BIO Announces a Collaboration with Onyx Pharmaceuticals worth up to US$550 Million



News & Press Releases Archive
2008 News & Press Releases
2007 News & Press Releases
2006 News & Press Releases
2005 News & Press Releases
2004 News & Press Releases
2003 News & Press Releases
2002 News & Press Releases
2001 News & Press Releases
2000 News & Press Releases

Back to top

Copyright © 2002-2009 S*BIO Pte Ltd. All rights reserved.